MedTrace Logo

Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

NCT03431948 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-02-16

No results posted yet for this study

Summary

Study to determine the best dose of stereotactic body radiation therapy (SBRT) to be administered in combination with immunotherapy drugs including urelumab, cabiralizumab and nivolumab .

Conditions

Interventions

DRUG

Nivolumab

Nivolumab 240 mg given by intravenous infusion every 2 weeks

DRUG

Cabiralizumab

Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks

DRUG

Urelumab

Urelumab 8 mg given by intravenous infusion every 4 weeks

RADIATION

Stereotactic Body Radiation Therapy

Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.

Sponsors & Collaborators

Principal Investigators

  • Jason Luke, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2020-02-29
Completion
2022-04-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03431948 on ClinicalTrials.gov